Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a biotech firm specializing in extended-release drug delivery, will present findings from a Phase 1b trial at the 20th ISDE World Congress for Esophageal Diseases. Their poster will focus on the initial results of their EP-104GI treatment for Eosinophilic Esophagitis, demonstrating the potential benefits of their DiffuSphere™ technology for targeted, stable drug delivery.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
